The sequencing of *Trypanosoma cruzi* genome revealed a high percentage of genes assigned with unknown function or with a role attributed only based on sequence similarity ([@B6], [@B15]). In order to improve this scenario and to add functional information to *T. cruzi* genes, our group previously constructed the p*Tc*GW platform, which is composed by plasmid vectors containing several N-terminal fusion tags ([@B2]). In the current work we improved the previous 1.0 version of the p*Tc*GW platform and created the p*Tc*GW 1.1 version by implementing three changes.

First, in order to make our platform fully flexible, we aimed that each restriction site was present only once in the vectors. For this, we replaced the *Xho*I restriction site 5'-flanking the resistance marker by side by side *Asc*I and *Age*I sites through two cloning steps. The obtained plasmid (p*Tc*6HisP-NH 1.1) containing N-terminal hexahistidine fusion tag comprises the backbone NH-vector of p*Tc*GW platform 1.1 version (modification steps described in Supplementary [Fig. 1](#f01){ref-type="fig"}). Second, to create vectors containing C-terminal fusion tags, the cassette comprising the 18S ribosomal promoter (RP), the first intergenic region (IR) (*Tc*UIR), start codon and the N-terminal 6His tag were excised from p*Tc*6HisP-NH 1.1 and replaced by a new cassette containing only the RP and *Tc*UIR. Next, we replaced the phleomycin resistance marker by neomycin and added a green fluorescent protein (GFP) fusion tag creating the p*Tc*GFPN-CO 1.1, backbone for the CO-vectors (Supplementary [Fig. 2](#f02){ref-type="fig"}). Third, for protein complex purification, we added either protein C (*P*rotC) or *P*rotC-TEV-*P*rotA (PTP) tags \[PTP amplified from [@B12]\] in both N and C-terminal vectors.

Fig. 1:available p*Tc*GW 1.1 vectors with amino and carboxy-terminal fusion tags. Arrows indicate the restrictions sites flanking each element of the vectors. *att*: attachment; *att*R1 and *att*R2: attachment sites required for Gateway® recombination; *ccd*B: gene for negative selection; Cm®: chloramphenicol selectable marker; CO: carboxy-terminal fusion; H: hygromycin; N: neomycin; NH: amino-terminal fusion; P: phleomycin; p: plasmid; RP: ribosomal promoter; Tag: the fusion tag used, such as green fluorescent protein (GFP), cyan fluorescent protein (CFP), *P*rotC-TEV-*P*rotA (PTP), protein C (*P*rotC) or hexahistidine (6xHis); *Tc*: *Trypanosoma cruzi*; *Tc*UIR: *T. cruzi*ubiquitin intergenic region.

Fig. 2:cellular localisation and overexpression of tagged proteins in *Trypanosoma cruzi*. A: western blot (WB) using total extract of epimastigotes wild-type (WT) and expressing *P*rotC-*T*EV-*P*rotA (PTP)-tagged proteins; B: detection of mRNA export factor Mex67 and nucleoporin Nup95 tagged at C-terminal extremes and nuclear export factor Crm1 tagged at N-terminal extreme of PTP tag by indirect immunofluorescence microscopy; C: analysis of protein expressed by TcCLB.506825.40 gene; C1: polyacrylamide gel electrophoresis of the purified protein fused to a hexahistidine tag; C2: WB analysis using a specific anti-TcCLB.506825.40 antibody and total extract of WT epimastigotes (epi) and metacyclic trypomastigotes (meta); C3: WB analysis using a specific anti-TcCLB.506825.40 antibody and protein extracts of epi and meta expressing the conserved hypothetical protein (TcCLB.506825.40).The lower band (a) corresponds to the endogenous protein and the upper band (b) corresponds to the GFP-tagged protein expressed in the p*Tc*GFPN-CO 1.1 vector; D: subcellular localisation of TcCLB.506825.40 protein fused with GFP in *T. cruzi* epi parasites; DIC: differential imaging contrast; K: kinetoplast; N: nucleus. Bar = 5 μm (B), 10 μm (D).

Finally, in order to broaden the applicability of these tools towards different assays we replaced the tag and/or resistance marker through single cloning steps, generating five different amino 1.1 and four carboxy 1.1 plasmids ([Fig. 1](#f01){ref-type="fig"}). Our destination vectors allow performing a range of functional assays to characterise *T. cruzi* genes, such as protein overexpression, identification of interactors and protein localisation. The sequences of the plasmids are available on GenBank (accessions described on Supplementary data 3). The sequences of primers here employed and all material and methods can be found in Supplementary data 4. We also provide technical details for users in the p*Tc*GW Platform Guideline. Briefly, the guide contains an explanation of how the Gateway^®^ cloning system works, instructions for primers design, recombination reactions, plasmids propagation, *T. cruzi*transfection and selection.

The basic structure of the platform characterised by the presence of a strong RP (18S), IR from the ubiquitin *locus* (*Tc*UIR) and the Gateway^®^cloning system are maintained from version 1.0. The RP, recognised by RNA polymerase I, ensures an efficient transcription of genes under its control and had already been successfully used in *T. cruzi*vectors (Martinez-Calvillo at al. 1997, [@B14]). IRs provide signals to drive the processing of pre-mRNAs transcribed in the long polycistronic units. In order to be functional *T. cruzi*mRNAs receive a 39-nucleotide splice-leader in the 5' region and a PolyA tail in the 3' region ([@B10]). Given the pivotal role of IRs, the functional elements of our vectors are flanked by *Tc*UIR, which had already been used in a *T. cruzi* vector (Wen at al. 2001) and is present three times in our system. Additionally, our destination vectors contain a Gateway^®^ cassette composed by the attachment (*att*) sites *att*R1 and *att*R2 required for recombination, the chloramphenicol selectable marker and *ccd*B gene for negative selection.

Here, to demonstrate that the modifications in the platform preserved its functionality, the plasmids p*Tc*PTPN-NH 1.1, p*Tc*PTPN-CO 1.1 and p*Tc*GFPN-CO 1.1 were used for protein overexpression and localisation assays.

The 117 kDa exportin Crm1 (TcCLB.511725.150) was cloned into the N-terminal PTP plasmid (p*Tc*PTPN-NH 1.1) whereas the 67 kDa mRNA export factor Mex67 (TcCLB.506127.20) and the 95 kDa nucleoporin Nup95 (TcCLB.510181.50) were inserted in the C-terminal PTP plasmid (p*Tc*PTPN-CO 1.1). [Fig. 2A](#f02){ref-type="fig"} shows that the recombinant proteins were successfully expressed with the expected molecular weight. Furthermore, *T. cruzi* Mex67 and Nup95 demonstrated nuclear localisation, same as described for the *Trypanosoma brucei* orthologue proteins ([@B9], [@B5]), whereas the exportin Crm1, which shuttles between nucleus and cytoplasm, was observed to localise in both compartments ([Fig. 2B](#f02){ref-type="fig"}).

To exemplify the usefulnes of p*Tc*GW vectors to characterise hypothetical proteins we used the plasmid p*Tc*GFPN-CO 1.1 to clone the 58.1 kDa conserved hypothetical protein TcCLB.506825.40. The polyclonal serum raised using the recombinant protein recognised both the endogenous and the GFP-tagged protein in epimastigotes and metacyclic trypomastigotes forms of *T. cruzi*([Fig. 2C](#f02){ref-type="fig"}). Additionally, the intracellular localisation of the GFP-tagged TcCLB.506825.40 could be determined, which is concentrated in the posterior region of *Dm*28c epimastigotes ([Fig. 2D](#f02){ref-type="fig"}).

A striking feature of p*Tc*GW 1.1 version refers to the versatility of the system. All elements of the 1.1 vectors are flanked by exclusive restriction sites allowing an easy exchange of each element of the vector in a single cloning step, such as promoter, fusion tags, resistance markers and IRs. This feature empowers the system through the range of opened options. For example, one can easily adapt the vectors for use in other trypanosomatid species by simply changing IRs and promoter if required. Furthermore, by selecting different IRs containing developmentally regulated 3'UTR signals, the expression can be controlled in a life-cycle stage dependent manner ([@B4], [@B3]). Additionally, colocalisation studies can be performed by combining different tags with resistance markers.

Another improvement in the 1.1 version consists in the possibility of choosing whether using N or C-terminal fusion tags. This represents a very important feature since signal peptides located at the N-terminal region of proteins might be hidden when fluorescent tags in this portion are used ([@B13]).

In the previous version of the platform, to sequentially purify protein complexes we used a TAP tag, which is composed by a duplicated *P*rotA followed by Tobacco Etch Virus (TEV) protease site and calmodulin binding peptide. However, the second step of TAP tag purification was not efficient ([@B2]), issue previously reported in the literature and overcame by using a PTP tag ([@B12]). To offer an alternative to TAP tag, our vectors now have either a PTP or a *P*rotC tag. The PTP tag allows performing two steps purification whereas *P*rotC tag on its own can be used for single step protein complex purifications.

The vectors from 1.1 version of p*Tc*GW platform are compatible with both high and low-throughput studies and had already been successfully used in different studies ([@B1], [@B7], [@B8]). Altogether the alterations presented at p*Tc*GW 1.1 platform were designed to easily allow any further customisation and are available for scientific community.
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